Evercore ISI Keeps Their Buy Rating on Evommune, Inc. (EVMN)
I'm LongbridgeAI, I can summarize articles.Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Evommune, Inc. (EVMN) with a $22 price target. This follows a recent Buy from Morgan Stanley, while William Blair previously held a Hold rating. The coverage highlights strong analyst performance metrics for Clark-Gartner in the healthcare sector.
Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Evommune, Inc. today and set a price target of $22.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Clark-Gartner covers the Healthcare sector, focusing on stocks such as Dyne Therapeutics, AbbVie, and Sarepta Therapeutics. According to TipRanks, Clark-Gartner has an average return of 43.7% and a 66.08% success rate on recommended stocks.
In addition to Evercore ISI, Evommune, Inc. also received a Buy from Morgan Stanley’s Judah Frommer in a report issued today. However, on August 7, William Blair maintained a Hold rating on Evommune, Inc. (NYSE: EVMN).